Current Investments
Paratek Pharmaceuticals Inc.
Thomas Bigger, Boston, MA, US
Paratek is engaged in the discovery and commercialization of new anti-infectives based on novel tetracycline structures that allow for antibacterial and anti-inflammatory properties.
PharmAbcine
Jin San Yoo, Seoul, South Korea
PharmAbcine develops fully human therapeutic monoclonal antibody for the treatment of cancer and inflammatory diseases. PharmAbcine is a spin-out from Korea Research Institute of Bioscience & Biotechnology (KRIBB).
Phenomix Corporation
Laura Shawver, San Diego, CA, US
Phenomix is a drug discovery and development company focused on proven targets in large markets. The company’s lead drug candidate, PHX1149, is in Phase II testing as an orally available treatment for type II diabetes.
Polyphor AG
Jean-Pierre Obrecht, Allschwil, CH
Polyphor delivers syntheses of focused libraries of small molecules and epitope mimetic proteins of high purity and in substantial quantity and performs lead optimization, utilizing rapid parallel synthesis production. In parallel, Polyphor develops its own drugs and has a drug candidate for hematopoietic stem cell transplantation in clinical phase I.
Portaero, Inc.
David Plough, Cupertino, CA, US
Portaero is a medical technology company developing a device for the treatment of chronic obstructive pulmonary diseases, in particular emphysema.
ProCertus BioPharm, Inc.
Paul M. Weiss, Madison, WI, US
Procertus aims to discover and develop products that will protect cancer patients against chemotherapy- and radiotherapy-induced dermatological and gastrointestinal side effects.
Proteostasis Therapeutics Inc.
Christopher Mirabelli, Cambridge, MA, US
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body’s natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as Alzheimer’s disease, emphysema, Huntington’s disease, and type II diabetes.
PTC Therapeutics Inc.
Stuart Peltz, South Plainfield, NJ, USA
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
Pulmatrix, Inc.
Robert Connelly, CEO, Lexington, MA
Pulmatrix is discovering a new class of host-targeted therapies that treat, prevent and help control a broad range of respiratory infections and progressive respiratory diseases. Pulmatrix’s innovative pathogen independent approach harnesses the airway and lungs own natural biophysical and host defense mechanisms, offering potential for individual therapies that treat serious respiratory diseases including influenza, rhinovirus, COPD, asthma and cystic fibrosis.